Table 1.
Stimuli | Model/Species | Disease Model | Administration/Protocol | Mechanism of Oxidative Stress | Ref. |
---|---|---|---|---|---|
N-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) |
Male C57BL/6 mice (20–25 g) | PD, neurodegeneration |
Intraperitoneal injection of MPTP (20 mg/kg), two times at 4 h intervals daily for 5 days, followed by oral administration of Sophora tomentosa (25 mg/kg, 50 mg/kg, and 100 mg/kg) for 15 consecutive days until behavioral tests |
|
[88] |
Rotenone | Rotenone-induced Sprague–Dawley and Lewis rats | PD | Infusion of a 2–3 mg/kg dose of rotenone per day via a jugular vein cannula attached to a subcutaneous osmotic minipump |
|
[89] |
Paraquat (N, N′-dimethyl-4-4′-bipiridinium) | Human neuroblastoma SH-SY5Y cells | PD | Treated with paraquat (0.5 mM PQ) for 48 h |
|
[90] |
Hydrogen peroxide (H2O2) | SH-SY5Y cells | PD, AD, Huntington’s disease |
Incubation with varying concentrations of H2O2 (0 to 250 µM) for 30 min, followed by evaluation of cell viability |
|
[91,92] |
6-hydroxydopamine (6-OHDA) | SH-SY5Y cells | PD, AD, and dementia | Cells incubated with 200 µM of 6-OHDA for 24 h with or without hyperoxide or NAC pretreatment |
|
[93] |
Glutamate analog; homocysteate quisqualate ibotenate |
Neuronal hybridoma cell line, N18-RE-105 mouse neuroblastoma cells | ALS, AD, dementia, PD, multiple sclerosis (MS) | Continuous exposure of cells to ʟ-glutamate (1–10 mM) or quisqualate (0.1–1.0 mM) for 5 min |
|
[94,95] |
Mycotoxin 3-nitropropionic acid (3-NP) |
Male Wistar rats (300–350 g) | Huntington disease | Intraperitoneal administration of 3-NP (10 mg/kg) |
|
[96] |
Buthionine sulfoximine (BSO) | Hippocampus-derived immortalized cell line (HT22) | Chronic psychological stress | Treatment with 1 mM BSO for 14 h |
|
[97] |
Tunicamycin | SH-SY5Y cells | Endoplasmic reticulum stress | Incubation with 1 μM tunicamycin |
|
[98] |
RNAi | Drosophila | Oxidative damage | Knockdown of SOD2 using the Gal4/UAS system to express SOD2 inverted repeat (Sod2-IR) transgenes |
|
[99] |